{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:18:02Z","timestamp":1793852282500,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this study was to report denosumab induced MRONJ cases, and investigate the factors affecting the occurrence of MRONJ in patients who underwent denosumab and invasive dental treatment (especially tooth extraction) between October 2016 and March 2020. Four of the 98 patients developed MRONJ before and after tooth extraction. The participants were divided into two groups: receiving only denosumab (n\u2009=\u200951) and receiving bisphosphonate as first treatment and denosumab as second treatment (n\u2009=\u200947). There was no significant difference between groups in the occurrence of MRONJ and factors affecting MRONJ. Two out of 4 patients developed MRONJ regardless of invasive treatment after denosumab administration and proceeded with extraction; one patient developed MRONJ after denosumab administration and extraction. The other patient underwent a tooth extraction without osteoporosis treatment, and non-identified MRONJ developed after denosumab administration. MRONJ cases reported in this study show that MRONJ can develop as chronic inflammation without invasive dental treatment; therefore, implementing preventive dental treatment before initiating denosumab treatment is necessary to reduce the occurrence of MRONJ.<\/jats:p>","DOI":"10.1038\/s41598-022-11615-9","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T09:03:44Z","timestamp":1653296624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-9633","authenticated-orcid":false,"given":"Seoyeon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0603-619X","authenticated-orcid":false,"given":"Jaeyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-9554","authenticated-orcid":false,"given":"Jin Hoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-1067","authenticated-orcid":false,"given":"Ki-Yeol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-4004","authenticated-orcid":false,"given":"Hyung Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-1156","authenticated-orcid":false,"given":"Wonse","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"11615_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41584-019-0172-3","volume":"15","author":"E Seeman","year":"2019","unstructured":"Seeman, E. & Martin, T. J. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat. Rev. Rheumatol. 15, 225\u2013236. https:\/\/doi.org\/10.1038\/s41584-019-0172-3 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"11615_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-018-0439-3","volume":"13","author":"AA Yusuf","year":"2018","unstructured":"Yusuf, A. A. et al. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women. Arch. Osteoporos 13, 33. https:\/\/doi.org\/10.1007\/s11657-018-0439-3 (2018).","journal-title":"Arch. Osteoporos"},{"key":"11615_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber, J., Reichenbach, S., Ziswiler, H. R., Studer, U. & Lehmann, T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J. Bone Miner. Res. 35, 1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962 (2020).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback, D. et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update. J. Clin. Endocrinol. Metab. 105, 587. https:\/\/doi.org\/10.1210\/clinem\/dgaa048 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"11615_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell, R. et al. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"11615_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch, H. Bisphosphonates: Mechanisms of action. Endocr. Rev. 19, 80\u2013100. https:\/\/doi.org\/10.1210\/edrv.19.1.0325 (1998).","journal-title":"Endocr. Rev."},{"key":"11615_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/cia.s3333","volume":"4","author":"P Geusens","year":"2009","unstructured":"Geusens, P. Emerging treatments for postmenopausal osteoporosis: Focus on denosumab. Clin. Interv. Aging 4, 241\u2013250. https:\/\/doi.org\/10.2147\/cia.s3333 (2009).","journal-title":"Clin. Interv. Aging"},{"key":"11615_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis, O. et al. Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 127, 117\u2013135. https:\/\/doi.org\/10.1016\/j.oooo.2018.09.008 (2019).","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"11615_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115676","volume":"141","author":"D Govaerts","year":"2020","unstructured":"Govaerts, D. et al. Adjuvant therapies for MRONJ: A systematic review. Bone 141, 115676. https:\/\/doi.org\/10.1016\/j.bone.2020.115676 (2020).","journal-title":"Bone"},{"key":"11615_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update. J. Oral Maxillofac. Surg. 72, 1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031 (2014).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"11615_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.bdj.2017.79","volume":"222","author":"N Tanna","year":"2017","unstructured":"Tanna, N., Steel, C., Stagnell, S. & Bailey, E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br. Dent. J. 222, 121\u2013125. https:\/\/doi.org\/10.1038\/sj.bdj.2017.79 (2017).","journal-title":"Br. Dent. J."},{"key":"11615_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/s0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx, R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 61, 1115\u20131117. https:\/\/doi.org\/10.1016\/s0278-2391(03)00720-1 (2003).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"11615_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan, A. A. et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J. Bone Miner. Res. 30, 3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR14","doi-asserted-by":"publisher","DOI":"10.5395\/rde.2019.44.e42","volume":"44","author":"M Song","year":"2019","unstructured":"Song, M. Dental care for patients taking antiresorptive drugs: A literature review. Restor. Dent. Endod. 44, e42. https:\/\/doi.org\/10.5395\/rde.2019.44.e42 (2019).","journal-title":"Restor. Dent. Endod."},{"key":"11615_CR15","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","volume":"38","author":"M Kajizono","year":"2015","unstructured":"Kajizono, M. et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: A retrospective cohort study. Biol. Pharm. Bull. 38, 1850\u20131855. https:\/\/doi.org\/10.1248\/bpb.b15-00385 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"11615_CR16","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/jco.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28, 5132\u20135139. https:\/\/doi.org\/10.1200\/jco.2010.29.7101 (2010).","journal-title":"J. Clin. Oncol."},{"key":"11615_CR17","first-page":"33","volume":"61","author":"DD Damm","year":"2013","unstructured":"Damm, D. D. & Jones, D. M. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen. Dent. 61, 33\u201338 (2013).","journal-title":"Gen. Dent."},{"key":"11615_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein, J. W. et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J. Am. Dent. Assoc. 142, 1243\u20131251. https:\/\/doi.org\/10.14219\/jada.archive.2011.0108 (2011).","journal-title":"J. Am. Dent. Assoc."},{"key":"11615_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523. https:\/\/doi.org\/10.1016\/s2213-8587(17)30138-9 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"11615_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings, S. R. et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190\u2013198. https:\/\/doi.org\/10.1002\/jbmr.3337 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR21","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341\u20131347. https:\/\/doi.org\/10.1093\/annonc\/mdr435 (2012).","journal-title":"Ann. Oncol."},{"key":"11615_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan, K., McGowan, T. & Ivanovski, S. Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis. 24, 527\u2013536. https:\/\/doi.org\/10.1111\/odi.12708 (2018).","journal-title":"Oral Dis."},{"key":"11615_CR23","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.ajpath.2018.06.019","volume":"188","author":"T Kim","year":"2018","unstructured":"Kim, T. et al. Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw-like lesion in mice. Am. J. Pathol. 188, 2318\u20132327. https:\/\/doi.org\/10.1016\/j.ajpath.2018.06.019 (2018).","journal-title":"Am. J. Pathol."},{"key":"11615_CR24","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx, R. E., Sawatari, Y., Fortin, M. & Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63, 1567\u20131575. https:\/\/doi.org\/10.1016\/j.joms.2005.07.010 (2005).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"11615_CR25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","volume":"71","author":"C Tsao","year":"2013","unstructured":"Tsao, C. et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J. Oral Maxillofac. Surg. 71, 1360\u20131366. https:\/\/doi.org\/10.1016\/j.joms.2013.02.016 (2013).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"11615_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-020-03602-z","author":"P Paschalidi","year":"2020","unstructured":"Paschalidi, P. et al. The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw. Clin. Oral Investig. https:\/\/doi.org\/10.1007\/s00784-020-03602-z (2020).","journal-title":"Clin. Oral Investig."},{"key":"11615_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jcms.2017.02.023","volume":"45","author":"F Wehrhan","year":"2017","unstructured":"Wehrhan, F. et al. Macrophage and osteoclast polarization in bisphosphonate associated necrosis and osteoradionecrosis. J. Craniomaxillofac. Surg. 45, 944\u2013953. https:\/\/doi.org\/10.1016\/j.jcms.2017.02.023 (2017).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"11615_CR28","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/jbmr.1894","volume":"28","author":"B Kang","year":"2013","unstructured":"Kang, B. et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Miner. Res. 28, 1631\u20131640. https:\/\/doi.org\/10.1002\/jbmr.1894 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/jbmr.2097","volume":"29","author":"TL Aghaloo","year":"2014","unstructured":"Aghaloo, T. L. et al. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J. Bone Miner. Res. 29, 843\u2013854. https:\/\/doi.org\/10.1002\/jbmr.2097 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bone.2016.06.011","volume":"90","author":"A Soundia","year":"2016","unstructured":"Soundia, A. et al. Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease. Bone 90, 133\u2013141. https:\/\/doi.org\/10.1016\/j.bone.2016.06.011 (2016).","journal-title":"Bone"},{"key":"11615_CR31","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jbmr.379","volume":"26","author":"TL Aghaloo","year":"2011","unstructured":"Aghaloo, T. L. et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Miner. Res. 26, 1871\u20131882. https:\/\/doi.org\/10.1002\/jbmr.379 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR32","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.joms.2014.07.004","volume":"72","author":"S Cheong","year":"2014","unstructured":"Cheong, S. et al. Bisphosphonate uptake in areas of tooth extraction or periapical disease. J. Oral Maxillofac. Surg. 72, 2461\u20132468. https:\/\/doi.org\/10.1016\/j.joms.2014.07.004 (2014).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"11615_CR33","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1096\/fj.201901819RR","volume":"34","author":"R Elsayed","year":"2020","unstructured":"Elsayed, R. et al. Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw. FASEB J. 34, 2595\u20132608. https:\/\/doi.org\/10.1096\/fj.201901819RR (2020).","journal-title":"FASEB J."},{"key":"11615_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jbmr.1769","volume":"28","author":"S Kalyan","year":"2013","unstructured":"Kalyan, S., Quabius, E. S., Wiltfang, J., M\u00f6nig, H. & Kabelitz, D. Can peripheral blood \u03b3\u03b4 T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J. Bone Miner. Res. 28, 728\u2013735. https:\/\/doi.org\/10.1002\/jbmr.1769 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"11615_CR35","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.Ccr-13-0042","volume":"19","author":"Q Zhang","year":"2013","unstructured":"Zhang, Q. et al. IL-17-mediated M1\/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin. Cancer Res. 19, 3176\u20133188. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0042 (2013).","journal-title":"Clin. Cancer Res."},{"key":"11615_CR36","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/ijms22031323","volume":"22","author":"M Weber","year":"2021","unstructured":"Weber, M. et al. Zoledronate causes a systemic shift of macrophage polarization towards M1 in vivo. Int. J. Mol. Sci. 22, 1323. https:\/\/doi.org\/10.3390\/ijms22031323 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"11615_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00784-014-1273-7","volume":"19","author":"S Hoefert","year":"2015","unstructured":"Hoefert, S., Schmitz, I., Weichert, F., Gaspar, M. & Eufinger, H. Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): Evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases. Clin. Oral Investig. 19, 497\u2013508. https:\/\/doi.org\/10.1007\/s00784-014-1273-7 (2015).","journal-title":"Clin. Oral Investig."},{"key":"11615_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115308","volume":"135","author":"H Hayano","year":"2020","unstructured":"Hayano, H. et al. Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. Bone 135, 115308. https:\/\/doi.org\/10.1016\/j.bone.2020.115308 (2020).","journal-title":"Bone"},{"key":"11615_CR39","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam, A. et al. Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 233, 6425\u20136440. https:\/\/doi.org\/10.1002\/jcp.26429 (2018).","journal-title":"J. Cell. Physiol."},{"key":"11615_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173090","volume":"877","author":"C Yunna","year":"2020","unstructured":"Yunna, C., Mengru, H., Lei, W. & Weidong, C. Macrophage M1\/M2 polarization. Eur. J. Pharmacol. 877, 173090. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173090 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"11615_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115560","volume":"141","author":"S Tamaki","year":"2020","unstructured":"Tamaki, S. et al. Dynamic polarization shifting from M1 to M2 macrophages in reduced osteonecrosis of the jaw-like lesions by cessation of anti-RANKL antibody in mice. Bone 141, 115560. https:\/\/doi.org\/10.1016\/j.bone.2020.115560 (2020).","journal-title":"Bone"},{"key":"11615_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/adj.12648","volume":"63","author":"A Khominsky","year":"2018","unstructured":"Khominsky, A. & Lim, M. \u201cSpontaneous\u201d medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust. Dent. J. 63, 441\u2013454. https:\/\/doi.org\/10.1111\/adj.12648 (2018).","journal-title":"Aust. Dent. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11615-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:49:38Z","timestamp":1669330178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11615-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11615"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11615-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8641"}}